Clinical Trial Update: Low Dose Rituximab as a First Line Biologic Therapy for the Treatment of DMARD Resistant Patients With Rheumatoid Arthritis [Phase 4]

View source ↗

Summary

This is a Phase 4 trial update evaluating low-dose rituximab as a first-line biologic therapy for DMARD-resistant rheumatoid arthritis. The study status is comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Mashhad University of Medical Sciences | Conditions: DMARD Resistant Rheumatoid Arthritis | Phase 4 | Status: COMPLETED